
cofounder/ceo @cognitiinc | investing in scientific assets in femtech x longevity @athenabiorg | forbes 30u30 asia (not arrested yet)
Hyderabad
Joined January 2020
- Tweets866
- Following595
- Followers392
- Likes16.1K
There wouldn’t have been a @cognitiinc if it weren’t for @srajagopalan and her insane belief in future of this country! ❤️🇮🇳
What @srajagopalan is doing with Emergent Ventures in India will one day be in the history books.
5
245
Jhillika Trisal retweeted
Women's fertility medicine has spent decades reacting to crisis rather than protecting health.
Dr. Mario Cordero's @CorderoMarioD new Science Advances paper flips that: a small molecule to protect ovarian reserve before the damage starts.
Jhillika Trisal retweeted
Saying it again - cellular reprogramming for ovaries makes a lot of sense. It is truly the best organ to study longitudinally.
There are labs already experimenting with this and I feel like @altos_labs hinted at it on their NYT article. (If they have not gone full AI).
I also know scientists who did reprogramming and moved on from this because they no longer believe it possible without unleashing irreparable toxicity and other problems.
At least there is funding to try this moonshot!
Jhillika Trisal retweeted
Knock out NLRP3 completely in mice → longer, healthier lives. So biotech poured money into inhibiting it.
Problem: drugs don't knock targets out in humans, they dial them down.
Dr. Mario Cordero @CorderoMarioD’s latest research modelled that, and it showed that partial inhibition actually accelerated aging because a backup protein, NLRP1, surged.
The fix: create dual inhibitors that block both at once.
More about his research in our latest newsletter 👇
Jhillika Trisal retweeted
I see a lot of people cosplay as underdogs on X while sitting on millions raised from Tier 1 funds.
Want to meet someone who truly is climbing Mount Everest?
Dr. Mario Cordero is looking at an hot target but in an area where more data is needed.
The problem in drug development around sex specific targets is something we don’t talk about enough in biotech.
Knock out NLRP3 completely in mice → longer, healthier lives. So biotech poured money into inhibiting it.
Problem: drugs don't knock targets out in humans, they dial them down.
Dr. Mario Cordero @CorderoMarioD’s latest research modelled that, and it showed that partial inhibition actually accelerated aging because a backup protein, NLRP1, surged.
The fix: create dual inhibitors that block both at once.
More about his research in our latest newsletter 👇
Jhillika Trisal retweeted
By the time a woman hears "diminished ovarian reserve," the options have already narrowed to working around what's left.
Dr. Mario Cordero @CorderoMarioD is trying to protect the reserve before the damage hits, starting with women facing early menopause after chemo.
New in @ScienceAdvances 👇
Jhillika Trisal retweeted
An academic in a small Spanish lab, working on a target two IPO'd longevity biotechs are now circling.
Dr. Mario Cordero @CorderoMarioD chose the harder path: developing it first for women facing menopause after cancer, even though faster applications sit in his pipeline.
Learn more about the science worth backing 👇
Jhillika Trisal retweeted
Exciting news on IVG.
Congrats to @mattkrisiloff and the Conception team!
I’m so excited to share this update on @Conception –
We’ve generated the first early human eggs derived from stem cells.
This is a big deal -- the potential to redefine fertility is real.
Jhillika Trisal retweeted
For most of the body, aging shows up slowly.
For ovaries, the clock can run years ahead, and for women after chemo, decades ahead.
Dr. Mario Cordero's @CorderoMarioD new Science Advances paper is working to protect ovarian reserve before that window closes 👇
Jhillika Trisal retweeted
Polyendocrine Metabolic Ovarian Syndrome (PMOS) is the new name for the condition previously known as Polycystic Ovary Syndrome (PCOS), which impacts 1 in 8 women worldwide.
The old name focused on ovarian cysts and now better reflects the reality of this condition.
Jhillika Trisal retweeted
For those tho don’t know us @athenabiorg had deployed 1.5M to 14 labs across research, fellowships, and academic conferences like @EOvaryWorkshop and @BritFertSoc.
One of our funded researchers is working on an inflammation therapeutic to target Diminished Ovarian Reserve,
We have helped spin out a menopause prediction startup @Lifeaheadinc,
And are supporting companies like Rejoovenate Bio doing oocyte reprogramming to improve IVF.
We have developed a system to deploy capital both to translational research and investments into companies.
Jhillika Trisal retweeted
We have been at the forefront of ovarian aging for the last three years. Read more about why, to us, reproductive health and IVF could be improved 👇
Some points about @rivatez’s amazing article vis-à-vis the IVF industry and ovarian aging and health.
1. PE-backed entities are responsible for over 50% of all IVF cycles performed in the United States. This means that in many ways, women are the product. You can deduce from that what you want.
2. One thing that did not sit right with me in the @WorksInProgMag article was that the title “Science has largely solved the problem of reproductive ageing for women, but they have to prepare while they’re young” was largely misleading as reproductive ageing is far from solved. IVF is 48 years old, efficacy rates are still very low and women are still going through very intrusive medical procedures. @AlmostMedia speaks of the permanent damage and huge toll it can take on women.
I was thrilled Riva pointed out on her last chapter that to tackle the problem we need to look at biology. VCs tell me all the time they are into funding fertility tech, but most of them put bets on infrastructure, not underlying biology. It reminded me when I was looking at longevity, going to an aging conference, and everyone was talking about new systems to manage retirement homes, rather than treating biology to avoid these places. We optimize and fund the infrastructure that keeps us in old systems.
3. Ovarian health and aging is the next frontier in reproductive health. But for the record it is still extremely underfunded. The @BuckInstitute that Riva mentioned has not had grants for a while. I have researchers messaging me about projects that are loosing @NIH funding or looking for capital constantly. This is for basic research. For private markets it is the same. Artificial womb companies have an easier time getting capital than companies that are creating solutions to increase success rates in IVF. For the record I am all for the exo womb, but tech that has no chance of getting to patients for a while is more capitalized in the early stages than something that could be with patients in 3 years.
This brings me to Gameto, which the article mentions and is the one company everyone knows. Just because we can name one company it does not mean we solved the issue. One player is not enough. @GametoGen is also a very special case because its chairman is a very well known and successful tech and IVF industry entrepreneur. I hope they succeed in their phase 3 and IPO to become the first unicorn in biotech for women’s health. Top tier funds invested as well as anyone who has been into women’s health for a while. This would be a true win for the industry and bring the attention and capital inflow it needs. Not the faux exits and distress asset sales that have been touted as wins as of late. With that said, most investors are priced out of Gameto, or too late. Let me be clear that there are new opportunities and other tech we should be funding.
4. Ovarian cryopreservation is being done already in places like Brazil by groups like ProFam. I am huge advocate for and we have featured them for a while
now but remember this is only within a certain window and highly invasive. It’s not a silver bullet either.
5. I have a wager that the first thing we are going to “rejuvenate” or “solve aging” for is ovarian aging. But it needs more capital.
If you are someone looking to support research as a philanthropist or companies as an investor, this is what we have been doing for the three years now @athenabiorg. Our mandate was “funding translational research in women’s health.” Ultimately, our moat became ovarian health.
We know the science and people you could be putting your money into if you care about this subject.
Jhillika Trisal retweeted
There are two things common between the founders of Zerodha, Zomato, OpenAI, Amazon, Microsoft, Google, Spotify. First, they all are billionaires. Second, they all are investing or building in healthcare.
It’s never been a better time that now to build something to make people stay healthy. We've made 40+ investments in startups helping Indians to stay healthy and fit. Healthcare is the future. Everyone wants to build something & everyone wants to get into it. The most valuable company of the future will be a healthcare company.
Jhillika Trisal retweeted
Walked through the exhibition of assistive products, solutions and smart technologies at the Inclusive Education Summit.
Impressed by the innovative and world-class solutions of our start-ups for making education inclusive and meeting the diverse needs of CwSN and PWDs. Ensuring dignity, access and equal opportunities for our Divyang population is a collective responsibility. We have to continue to do more for our Divyang brothers and sisters, including through laws, accessible infrastructure, inclusive policies and innovations for actualising the goal of Viksit Bharat.
Jhillika Trisal retweeted
📢Excited to announce the 1991 Fellowship @mercatus - to find and back the next generation of policy thinkers working on state-level deregulation in India.
Funding, mentorship, and support to turn good ideas into policy.
Apply here: mercatus.org/1991-fellowship.
Deadline Feb 28.
Jhillika Trisal retweeted
I used to think the longevity community was better than the women’s health one - but progress is lacking in both because of a lack of collaboration.
Everyone wants to have their own org, work on top of each other and be the leader. Instead of making things easier to navigate - it’s a competition for funding and attention.
Zero sum games are keeping us down.
Jhillika Trisal retweeted
We met 50+ longevity companies last year. Most are doing literally nothing but want to raise a lot of money because there is a global trend around ageing & health optimisation. Maybe a lot of influencer podcasts are seeding this.
Most are building high ticket longevity clinics and programs aimed at urban elites. And selling an extensive list of blood markers that has no clear clinical proof on outcomes. Lots of supplements, IV therapies, and optimisation protocols borrowed from global biohacking trends.
Some are capex heavy that doesn’t seem fair to venture models for scale.
What’s working is delivering programs where the primary product is not longevity but focused on preventive health & chronic care. Create diagnostics that can show real improvements as a proof that indicates outcomes. And solutions around productivity, elder health, or injury prevention.
This business needs founding team who have a combination of medicine & growth experience.
What’s not working are models that assume aspiration would convert into long term behaviour and repeat spend. High CAC, low retention. Don’t over sell future lifespan instead of managing present day health issues. Don’t make apps that promise outcomes and ask for daily data inputs.
You can make money in this business with good margins. The opportunity lies in systems that improve health today, track outcomes over time, and earn trust gradually. But are also manageable by everyday folks.






















